Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | SR8278 | CTRPv2 | pan-cancer | AAC | -0.059 | 0.7 |
mRNA | BRD-K03911514 | CTRPv2 | pan-cancer | AAC | -0.025 | 0.7 |
mRNA | MLN2480 | CTRPv2 | pan-cancer | AAC | 0.025 | 0.7 |
mRNA | prochlorperazine | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-K58730230 | CTRPv2 | pan-cancer | AAC | -0.032 | 0.7 |
mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | IPR-456 | CTRPv2 | pan-cancer | AAC | -0.017 | 0.7 |
mRNA | BRD-A02303741:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.015 | 0.7 |